abstract: Most @entity5 rely on aerobic glycolysis to generate energy and metabolic intermediates. To maintain a high glycolytic rate, cells must efficiently export @entity880 through the proton-coupled @entity3338 transporters ( @entity72157 ). These transporters require a chaperone, @entity34403 (BSG) for trafficking to the plasma membrane and function.To validate the key role of these transporters in @entity2 , we first analysed the expression of @entity72157 and BSG in 50 @entity1149 (NSCLC) cases. These proteins were specifically upregulated in @entity5 tissues. We then disrupted BSG in three NSCLC cell lines (A549, H1975 and H292) via 'Zinc-Finger Nucleases'. The three homozygous BSG-/- cell lines displayed a low MCT activity (10- to 5-fold reduction, for @entity34742 and @entity71808 , respectively) compared to wild-type cells. Consequently, the rate of glycolysis, compared to the wild-type counterpart, was reduced by 2.0- to 3.5-fold, whereas the rate of respiration was stimulated in BSG-/- cell lines. Both wild-type and BSG-null cells were extremely sensitive to the mitochondria inhibitor @entity2449 / @entity18706 in normoxia. However, only BSG-null cells, independently of their @entity2448 status, remained sensitive to @entity37005 in @entity519 in vitro and @entity5 growth in @entity19 . Our results demonstrate that inhibiting glycolysis by targeting @entity880 export sensitizes NSCLC to @entity18706 .

title: Disruption of @entity34403 decreases XXXX export and sensitizes @entity1149 to biguanides independently of the @entity2448 status.

answer: @entity880 :: (MESH:D019344,Chemical) :: ['lactic acid']


abstract: Most @entity5 rely on aerobic glycolysis to generate energy and metabolic intermediates. To maintain a high glycolytic rate, cells must efficiently export @entity880 through the proton-coupled @entity3338 transporters ( @entity72157 ). These transporters require a chaperone, @entity34403 (BSG) for trafficking to the plasma membrane and function.To validate the key role of these transporters in @entity2 , we first analysed the expression of @entity72157 and BSG in 50 @entity1149 (NSCLC) cases. These proteins were specifically upregulated in @entity5 tissues. We then disrupted BSG in three NSCLC cell lines (A549, H1975 and H292) via 'Zinc-Finger Nucleases'. The three homozygous BSG-/- cell lines displayed a low MCT activity (10- to 5-fold reduction, for @entity34742 and @entity71808 , respectively) compared to wild-type cells. Consequently, the rate of glycolysis, compared to the wild-type counterpart, was reduced by 2.0- to 3.5-fold, whereas the rate of respiration was stimulated in BSG-/- cell lines. Both wild-type and BSG-null cells were extremely sensitive to the mitochondria inhibitor @entity2449 / @entity18706 in normoxia. However, only BSG-null cells, independently of their @entity2448 status, remained sensitive to @entity37005 in @entity519 in vitro and @entity5 growth in @entity19 . Our results demonstrate that inhibiting glycolysis by targeting @entity880 export sensitizes NSCLC to @entity18706 .

title: Disruption of XXXX decreases @entity880 export and sensitizes @entity1149 to biguanides independently of the @entity2448 status.

entities_list: @entity2449 :: ('MESH:D008687', 'Chemical') :: ['metformin']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancers', 'tumour']

entities_list: @entity2 :: ('MESH:D008175', 'Disease') :: ['lung cancer']

entities_list: @entity1149 :: ('MESH:D002289', 'Disease') :: ['non-small lung cancer']

entities_list: @entity37005 :: ('MESH:D001645', 'Chemical') :: ['biguanides']

entities_list: @entity880 :: ('MESH:D019344', 'Chemical') :: ['lactic acid']

entities_list: @entity3338 :: ('CHEBI:35757', 'Chemical') :: ['monocarboxylate']

entities_list: @entity18706 :: ('MESH:D010629', 'Chemical') :: ['phenformin']

answer: @entity34403 :: (12215(Tax:10090),Gene) :: ['BASIGIN']


abstract: Cognitive accounts of gambling suggest that the experience of almost winning-so-called 'near-misses'-encourage continued play and accelerate the development of @entity11532 ( @entity11532 ) in vulnerable individuals. One explanation for this effect is that near-misses signal imminent winning outcomes and heighten reward expectancy, galvanizing further play. Determining the neurochemical processes underlying the drive to gamble could facilitate the development of more effective treatments for @entity11532 . With this aim in mind, we evaluated @entity35 ' performance on a novel model of slot machine play, a form of gambling in which near-miss events are particularly salient. Subjects responded to a series of three @entity11170 lights, loosely analogous to the wheels of a slot machine, causing the lights to set to 'on' or 'off'. A winning outcome was signaled if all three lights were illuminated. At the end of each trial, @entity35 chose between responding on the 'collect' lever, resulting in reward on win trials, but a time penalty on loss trials, or starting a new trial. @entity35 showed a marked preference for the collect lever when both two and three lights were illuminated, indicating heightened reward expectancy following near-misses similar to wins. Erroneous collect responses were increased by @entity4944 and the D(2) receptor agonist @entity11640 , but not by the D(1) receptor agonist @entity10432 or receptor subtype selective antagonists. These data suggest that @entity935 modulates reward expectancy following the experience of almost winning during slot machine play, via activity at D(2) receptors, and this may result in an enhancement of the near-miss effect and facilitate further gambling.

title: XXXX modulates reward expectancy during performance of a slot machine task in @entity35 : evidence for a 'near-miss' effect.

entities_list: @entity11640 :: ('MESH:D019257', 'Chemical') :: ['quinpirole']

entities_list: @entity935 :: ('MESH:D004298', 'Chemical') :: ['dopamine']

entities_list: @entity11532 :: ('MESH:D005715', 'Disease') :: ['pathological gambling', 'PG']

entities_list: @entity4944 :: ('MESH:D000661', 'Chemical') :: ['amphetamine']

answer: @entity935 :: (MESH:D004298,Chemical) :: ['Dopamine']


abstract: Cognitive accounts of gambling suggest that the experience of almost winning-so-called 'near-misses'-encourage continued play and accelerate the development of @entity11532 ( @entity11532 ) in vulnerable individuals. One explanation for this effect is that near-misses signal imminent winning outcomes and heighten reward expectancy, galvanizing further play. Determining the neurochemical processes underlying the drive to gamble could facilitate the development of more effective treatments for @entity11532 . With this aim in mind, we evaluated @entity35 ' performance on a novel model of slot machine play, a form of gambling in which near-miss events are particularly salient. Subjects responded to a series of three @entity11170 lights, loosely analogous to the wheels of a slot machine, causing the lights to set to 'on' or 'off'. A winning outcome was signaled if all three lights were illuminated. At the end of each trial, @entity35 chose between responding on the 'collect' lever, resulting in reward on win trials, but a time penalty on loss trials, or starting a new trial. @entity35 showed a marked preference for the collect lever when both two and three lights were illuminated, indicating heightened reward expectancy following near-misses similar to wins. Erroneous collect responses were increased by @entity4944 and the D(2) receptor agonist @entity11640 , but not by the D(1) receptor agonist @entity10432 or receptor subtype selective antagonists. These data suggest that @entity935 modulates reward expectancy following the experience of almost winning during slot machine play, via activity at D(2) receptors, and this may result in an enhancement of the near-miss effect and facilitate further gambling.

title: @entity935 modulates reward expectancy during performance of a slot machine task in XXXX : evidence for a 'near-miss' effect.

answer: @entity35 :: (10116,Species) :: ['rats']


abstract: OBJECTIVE: To determine the risk of newly recorded @entity583 ( @entity583 ) and @entity64 among incident GCA cases compared with controls from the general population. We also evaluated time trends during follow-up. METHODS: We conducted a matched cohort study (1996-2010) of all @entity1 with incident GCA from the province of British Columbia, Canada. We estimated incidence rates of @entity583 and @entity64 according to @entity66 duration. We calculated hazard ratios (HRs), adjusting for potential confounders. RESULTS: Among 809 individuals with GCA (mean age 75.9 years, 75.8% female), 83 developed @entity583 and 60 developed @entity64 , with corresponding incidence rates of 38.1 and 26.4/1000 @entity1 -years, respectively. Compared with non-GCA cases, the age-, sex- and entry time-matched HRs were 2.75 (95% CI 2.16, 3.50) for @entity583 and 2.21 (95% CI 1.68, 2.91) for @entity64 . When other covariates were adjusted for, the corresponding HRs were 1.77 (95% CI 1.29, 2.43) and 2.04 (95% CI 1.43, 2.93). The age-, sex- and entry time-matched HRs for @entity583 and @entity64 were highest during the first year after GCA diagnosis [4.76 (95% CI 3.29, 6.88) and 3.20 (95% CI 2.11, 4.87), respectively]. CONCLUSION: These findings provide general population-based evidence that GCA @entity1 are at a substantially increased risk of @entity65 . Increased monitoring for this potentially fatal outcome and its modifiable risk factors is warranted for GCA @entity1 .

title: Increased risk of XXXX in giant cell arteritis: a general population-based study.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'person']

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['GCA disease']

entities_list: @entity583 :: ('MESH:D009203', 'Disease') :: ['myocardial infarction', 'MI']

entities_list: @entity65 :: ('MESH:D002318', 'Disease') :: ['cardiovascular disease']

answer: @entity65 :: (MESH:D002318,Disease) :: ['cardiovascular disease']


abstract: @entity14870 G  en  e can cause severe losses in @entity579 . Cytochrome P450s play crucial roles in the metabolism of allelochemicals in herbivorous insects. Two novel P450 cDNAs, CYP6CV1 and CYP9A38, were cloned from the midgut of @entity14870 . CYP6CV1 encodes a protein of 500 @entity3689 residues, while CYP9A38-predicted protein has 531 @entity3689 residues. Both cDNA-predicted proteins contain the conserved functional domains for all P450s. Phylogenetic analyses showed that CYP6CV1 is grouped in the cluster containing CYP6B members, while CYP9A38 is in the cluster including CYP9 members. However, both clusters are contained in the same higher lineage. Homologous analysis revealed that CYP6CV1 is most similar to CYP6B8, CYP6B7, CYP6B6, CYP6B2, and CYP6B4 with the highest @entity3689 identity of 41%. CYP9A38 is closest to CYP9A17, CYP9A21, CYP9A20, and CYP9A19 with the highest @entity3689 identity of 66%. Studies of temporal expression profiles revealed that CYP9A38 showed a steady increase in mRNA level during the five instar stages, but a low-expression level in pupae, and then presented at a high-expression level again in adults. Similar expression patterns were obtained with CYP6CV1. In the fifth instar larvae, CYP6CV1 was mainly expressed in midgut and fat bodies, whereas CYP9A38 was mainly expressed in midgut. Expression studies also revealed a 3.20-fold over-expression of CYP6CV1 and 3.54-fold over-expression of CYP9A38 after larval exposure to host @entity579 resistance. Our results suggest that both CYP6CV1 and CYP9A38 may be involved in detoxification of @entity579 phytochemicals.

title: Identification and Expression of Two Novel Cytochrome P450 Genes, CYP6CV1 and CYP9A38, in XXXX (Lepidoptera: Pyralidae).

entities_list: @entity14870 :: ('437488', 'Species') :: ['Cnaphalocrocis medinalis', 'C. medinalis']

answer: @entity14870 :: (437488,Species) :: ['Cnaphalocrocis medinalis']


abstract: BACKGROUND: Host T-cell responses are associated with favorable outcomes in @entity43 ( @entity43 ), but it remains unclear how best to promote these responses in @entity1 . Toward this goal, we evaluated a panel of clinically relevant cytokines for the ability to enhance multiple T-cell effector functions (polyfunctionality) in the native @entity5 environment. METHODOLOGY/PRINCIPAL FINDINGS: Experiments were performed with resident @entity405 + and @entity404 + T cells in bulk ascites cell preparations from high-grade serous @entity43 @entity1 . T cells were stimulated with a-CD3 in the presence of 100% autologous ascites fluid with or without exogenous @entity1199 , IL-12, @entity8923 or @entity15787 , alone or in combination. T-cell proliferation (Ki-67) and function ( @entity379 , @entity310 , @entity1199 , @entity12868 , and @entity3220 expression) were assessed by multi-parameter flow cytometry. In parallel, 27 cytokines were measured in culture supernatants. While ascites fluid had variable effects on @entity405 + and @entity404 + T-cell proliferation, it inhibited T-cell function in most @entity1 samples, with @entity3220 , @entity379 , and @entity12868 showing the greatest inhibition. This was accompanied by reduced levels of @entity1356 , @entity1193 , @entity4666 , @entity4155 , @entity1261 , @entity2841 , @entity10557 , PDGF-bb, and @entity540 in culture supernatants. T-cell proliferation was enhanced by exogenous @entity1199 , but other T-cell functions were largely unaffected by single cytokines. The combination of @entity1199 with cytokines engaging complementary signaling pathways, in particular IL-12 and @entity8923 , enhanced expression of @entity379 , @entity310 , and @entity12868 in all @entity1 samples by promoting polyfunctional T-cell responses. Despite this, other functional parameters generally remained inhibited. CONCLUSIONS/SIGNIFICANCE: The @entity43 ascites environment disrupts multiple T-cell functions, and exogenous cytokines engaging diverse signaling pathways only partially reverse these effects. Our results may explain the limited efficacy of cytokine therapies for @entity43 to date. Full restoration of T-cell function will require activation of signaling pathways beyond those engaged by @entity1199 , IL-12, @entity8923 , and @entity15787 .

title: Polyfunctional T-cell responses are disrupted by the XXXX ascites environment and only partially restored by clinically relevant cytokines.

entities_list: @entity43 :: ('MESH:D010051', 'Disease') :: ['epithelial ovarian cancer', 'EOC']

entities_list: @entity1 :: ('9606', 'Species') :: ['patient', 'patients']

answer: @entity43 :: (MESH:D010051,Disease) :: ['ovarian cancer']


abstract: BACKGROUND: Obesity is a recognized risk factor for various @entity66 and several indices are used clinically to assess overall cardiometabolic risk. This study aims to determine the sensitivity of six anthropometric indices [Body mass index (BMI), waist, waist-to-hip ratio (WHR), waist-to-height ratio (WHtR), body adiposity index (BAI) and visceral adiposity index (VAI)] in determining @entity6 , @entity301 , @entity2299 , @entity101 and @entity209 ( @entity209 ) in Saudi adults recruited from two independent cohorts (2008-2009 and 2013-2014). METHODS: A total of 6,821 Saudi adults [2008-2009, N = 3,971 (1,698 males and 2,273 females); 2013-2014, N = 2,850 (926 males and 1,924 females)] aged 18-70 years old were included in this descriptive, cross-sectional study. Anthropometrics were obtained and fasting blood samples analyzed for @entity413 and lipids. BMI, WHR, WHtR, BAI and VAI were computed mathematically. RESULTS: VAI was the most sensitive index in determining DMT2 (AUC 0.72; p < 0.001) in the 2008-2009 cohort and @entity209 (AUC = 0.84; p < 0.001) in the 2013-2014 cohort. WHR was most discriminating for CHD in both cohorts (AUC 0.70 and 0.84 for 2008-2009 and 2013-2014, p values <0.001, respectively). WHtR was most sensitive but rather modest in determining @entity101 (AUC 0.66; p < 0.001), while waist circumference was most sensitive for @entity2299 (AUC 0.72; p < 0.001) in the 2008-2009 cohort and @entity209 (AUC 0.85; p < 0.001) in the 2013-2014 cohort. BAI was the least sensitive adiposity index. CONCLUSION: Sensitivity of adiposity indices regarding @entity66 highlight the importance of body fat distribution in determining overall cardiometabolic risk, with indices involving @entity1144 being more clinically significant than BMI and BAI. The sensitivity of these adiposity indices should be noted in assessing a particular @entity66 .

title: Sensitivity of various adiposity indices in identifying XXXX in Arab adults.

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension']

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['cardiometabolic disease', 'cardiometabolic diseases']

entities_list: @entity2299 :: ('MESH:D050171', 'Disease') :: ['dyslipidemia']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes mellitus type 2']

entities_list: @entity301 :: ('MESH:D003327', 'Disease') :: ['coronary heart disease']

entities_list: @entity1144 :: ('MESH:D056128', 'Disease') :: ['abdominal obesity']

entities_list: @entity209 :: ('MESH:D008659', 'Disease') :: ['metabolic syndrome', 'MetS']

entities_list: @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose']

answer: @entity66 :: (MESH:D004194,Disease) :: ['cardiometabolic diseases']


abstract: INTRODUCTION: The aim of this study was to examine whether the cumulative inflammatory burden is associated with an increase in arterial stiffness in a prospective cohort of @entity5144 ( @entity5144 ) @entity1 . METHODS: In total, 72 @entity5144 @entity1 were followed for a median of 6.5 years. Cumulative inflammatory burden was represented by the cumulative averages of repeated measures of erythrocyte sedimentation rate (ca-ESR) and @entity1851 (ca-CRP). Brachial-ankle pulse wave velocity ( @entity122 ) was measured at the last visit. We also included 47 healthy controls for @entity122 assessment. RESULTS: @entity122 was significantly higher in @entity5144 @entity1 compared with healthy controls after adjustment for age, gender and body weight (1466  29 cm/s versus 1323  38 cm/s, P=0.008). @entity5144 @entity1 were divided into two groups based on whether their @entity122 value is >= 1450 cm/s (High @entity122 group, N=38) or <1450 cm/s (Low @entity122 group, N=34). The High @entity122 group had a significantly higher ca-ESR (29 (19 to 44) versus 18 (10 to 32) mm/1st hour, P=0.005) and ca-CRP (0.7 (0.3 to 1.4) versus 0.4 (0.2 to 0.7) mg/dl, P=0.029). Using regression analysis, high ca-ESR (defined as >= 75th percentile: 37 mm/1st hour) was associated with a higher likelihood of being in the High @entity122 group (odds ratio (OR): 9.455 (1.939 to 46.093), P=0.005, adjusted for baseline clinical and cardiovascular risk factors; and 9.111 (1.875 to 44.275), P=0.006, adjusted for last visit parameters). CONCLUSIONS: Cumulative inflammatory burden, as reflected by ca-ESR, was associated with increased arterial stiffness in @entity5144 @entity1 even after adjustment for cardiovascular risk factors, emphasizing the important role of chronic @entity32 in accelerating the development of @entity65 in @entity5144 @entity1 .

title: Cumulative inflammatory burden is independently associated with increased arterial stiffness in @entity1 with XXXX : a prospective study.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation']

entities_list: @entity5144 :: ('MESH:D015535', 'Disease') :: ['PsA', 'psoriatic arthritis']

entities_list: @entity65 :: ('MESH:D002318', 'Disease') :: ['cardiovascular risks']

entities_list: @entity1851 :: ('1401', 'Gene') :: ['C-reactive protein']

answer: @entity5144 :: (MESH:D015535,Disease) :: ['psoriatic arthritis']


abstract: INTRODUCTION: The aim of this study was to examine whether the cumulative inflammatory burden is associated with an increase in arterial stiffness in a prospective cohort of @entity5144 ( @entity5144 ) @entity1 . METHODS: In total, 72 @entity5144 @entity1 were followed for a median of 6.5 years. Cumulative inflammatory burden was represented by the cumulative averages of repeated measures of erythrocyte sedimentation rate (ca-ESR) and @entity1851 (ca-CRP). Brachial-ankle pulse wave velocity ( @entity122 ) was measured at the last visit. We also included 47 healthy controls for @entity122 assessment. RESULTS: @entity122 was significantly higher in @entity5144 @entity1 compared with healthy controls after adjustment for age, gender and body weight (1466  29 cm/s versus 1323  38 cm/s, P=0.008). @entity5144 @entity1 were divided into two groups based on whether their @entity122 value is >= 1450 cm/s (High @entity122 group, N=38) or <1450 cm/s (Low @entity122 group, N=34). The High @entity122 group had a significantly higher ca-ESR (29 (19 to 44) versus 18 (10 to 32) mm/1st hour, P=0.005) and ca-CRP (0.7 (0.3 to 1.4) versus 0.4 (0.2 to 0.7) mg/dl, P=0.029). Using regression analysis, high ca-ESR (defined as >= 75th percentile: 37 mm/1st hour) was associated with a higher likelihood of being in the High @entity122 group (odds ratio (OR): 9.455 (1.939 to 46.093), P=0.005, adjusted for baseline clinical and cardiovascular risk factors; and 9.111 (1.875 to 44.275), P=0.006, adjusted for last visit parameters). CONCLUSIONS: Cumulative inflammatory burden, as reflected by ca-ESR, was associated with increased arterial stiffness in @entity5144 @entity1 even after adjustment for cardiovascular risk factors, emphasizing the important role of chronic @entity32 in accelerating the development of @entity65 in @entity5144 @entity1 .

title: Cumulative inflammatory burden is independently associated with increased arterial stiffness in XXXX with @entity5144 : a prospective study.

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: BACKGROUND: Because circulating antibodies against a variety of antigens have been detected in @entity1 with @entity301 , @entity2998 and those who have suffered a @entity64 , it is suspected that immune response may be one of the mechanisms of atherogenesis The objective of this study is to identify novel antibodies in @entity385 @entity1 by screening the expressed recombinant proteins using a @entity1 cDNA library (SEREX). METHODS: To identify the candidate antigens, cDNA library was screened by SEREX using plasma from ten @entity1 with @entity385 . Subsequently, via ELISA using recombinant proteins and synthetic peptides, the serum antibody levels were measured in two independent @entity1 /healthy donor (HD) cohorts (142 and 78 in the 2nd screening and a validation cohort, respectively). RESULTS: The initial screening resulted in the identification of six candidate antigens. Of these antigens, @entity32686 ( @entity32686 ) was determined to be the antigen associated with @entity64 (P   <   0.05) by ELISA with 2nd screening and validation cohort. Multifactorial logistic regression analysis showed that the increased levels of the @entity32686 antibodies ( @entity32686 -Abs) associated with @entity64 independent of other risk factors for @entity64 (P   <   0.05). Receiver operating curve analysis demonstrated that the area under the curve from ELISA using GST fusion @entity32686 and synthetic peptides (bRPA2-132) were 0.867 (95% CI: 0.798-0.936) and 0.971 (95% CI: 0.940-1.00), respectively. If the cut-off value of the bRPA2-132-Ab level was determined to be 0.334, the sensitivity and specificity of the antibody level as the diagnostic marker for @entity64 were 0.323 (95% CI: 0.209-0.453) and 1.00 (95% CI: 0.713-1.00), respectively. CONCLUSIONS: SEREX identified @entity32686 as the antigen associated with @entity385 and serum auto-antibodies against @entity32686 elevates in @entity64 @entity1 . @entity32686 -Abs could become a biomarker for the evaluation of @entity385 at risk.

title: Identification of XXXX -associated-antigens via screening of recombinant proteins from the @entity1 expression cDNA library (SEREX).

entities_list: @entity1 :: ('9606', 'Species') :: ['human', 'patients', 'patient']

entities_list: @entity2998 :: ('MESH:D002340', 'Disease') :: ['carotid atherosclerosis']

entities_list: @entity32686 :: ('6118', 'Gene') :: ['replication protein A2', 'RPA2']

entities_list: @entity385 :: ('MESH:D002544', 'Disease') :: ['ischemic stroke']

answer: @entity64 :: (MESH:D020521,Disease) :: ['stroke']


abstract: BACKGROUND: Because circulating antibodies against a variety of antigens have been detected in @entity1 with @entity301 , @entity2998 and those who have suffered a @entity64 , it is suspected that immune response may be one of the mechanisms of atherogenesis The objective of this study is to identify novel antibodies in @entity385 @entity1 by screening the expressed recombinant proteins using a @entity1 cDNA library (SEREX). METHODS: To identify the candidate antigens, cDNA library was screened by SEREX using plasma from ten @entity1 with @entity385 . Subsequently, via ELISA using recombinant proteins and synthetic peptides, the serum antibody levels were measured in two independent @entity1 /healthy donor (HD) cohorts (142 and 78 in the 2nd screening and a validation cohort, respectively). RESULTS: The initial screening resulted in the identification of six candidate antigens. Of these antigens, @entity32686 ( @entity32686 ) was determined to be the antigen associated with @entity64 (P   <   0.05) by ELISA with 2nd screening and validation cohort. Multifactorial logistic regression analysis showed that the increased levels of the @entity32686 antibodies ( @entity32686 -Abs) associated with @entity64 independent of other risk factors for @entity64 (P   <   0.05). Receiver operating curve analysis demonstrated that the area under the curve from ELISA using GST fusion @entity32686 and synthetic peptides (bRPA2-132) were 0.867 (95% CI: 0.798-0.936) and 0.971 (95% CI: 0.940-1.00), respectively. If the cut-off value of the bRPA2-132-Ab level was determined to be 0.334, the sensitivity and specificity of the antibody level as the diagnostic marker for @entity64 were 0.323 (95% CI: 0.209-0.453) and 1.00 (95% CI: 0.713-1.00), respectively. CONCLUSIONS: SEREX identified @entity32686 as the antigen associated with @entity385 and serum auto-antibodies against @entity32686 elevates in @entity64 @entity1 . @entity32686 -Abs could become a biomarker for the evaluation of @entity385 at risk.

title: Identification of @entity64 -associated-antigens via screening of recombinant proteins from the XXXX expression cDNA library (SEREX).

answer: @entity1 :: (9606,Species) :: ['human']


abstract: OBJECTIVES: Recently a biocompatible bone adhesive was introduced in addition to the sternal wires to expedite sternal union and improve @entity1 recovery. In this study we aim to objectively assess the biomarker of @entity158 in @entity1 who received the biocompatible bone adhesive. METHODS: A total of 62 @entity1 who underwent sternotomy were prospectively randomised to receive either conventional wire closure (CWC); 32 @entity1 or adhesive enhanced closure in addition to sternal wire (AEC); 30 @entity1 . @entity1 were monitored postoperatively at certain time intervals for incisional @entity158 , serum @entity650 ( @entity650 ) level, analgesia used and postoperative complications. All @entity1 were followed up for 4 weeks. RESULTS: The post-operative @entity158 scores with coughing were significantly higher in the CWC group at 24 hours and 48 hours. The postoperative @entity650 levels were significantly higher in the CWC group in comparison with the AEC group at 6 hours, 24 hours, and 48 hours. There were no significant differences in term of additional analgesia used. No adverse events from adhesive bone cement were observed during follow up. CONCLUSIONS: Adhesive-enhanced sternal closure resulted in modest @entity158 confirmed by @entity158 biomarker. Justification of its routine use requires larger multicentre study.

title: Effect of sternal closure with biological bone adhesive on XXXX visual analogue score and serum cytokine.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient']

entities_list: @entity158 :: ('MESH:D010146', 'Disease') :: ['pain', 'reduction of pain']

answer: @entity158 :: (MESH:D010146,Disease) :: ['pain']


abstract: The goal of this study was to compare biofilm synthesis among enterococci recovered from clinical samples (infection or colonization) of @entity1 as well as environmental samples in order to determine possible virulence factors and clonal relationship. During a two-year period, clinical samples (blood, catheter tips, bronchial secretions, wounds, peritoneal fluid, urine) and rectal swabs collected from hospitalized @entity1 as well as environmental water samples were tested for the presence of @entity797 and @entity797 faecium. Antibiotic susceptibility testing was performed by the disc diffusion method and Etest. Strains were tested for the presence of vanA, vanB, @entity10223 , ace and asp genes by PCR. Clones were identified by @entity20297 (SmaI). From infected @entity1 , 48 strains were identified: 24 @entity6375 (10 vanA-positive, 14 @entity2176 -susceptible) and 24 @entity797 (one vanA-positive, 23 @entity2176 -susceptible). Among 143 colonizing isolates, 134 were @entity6375 (58 vanA-positive, 11 vanB-positive, 65 @entity2176 -susceptible) and nine @entity797 (three vanA-positive, two vanB-positive, four @entity2176 -susceptible). Among 167 environmental water samples, 51 @entity797 and 19 @entity6375 isolates, all glycopeptide-susceptible, were recovered. In total, 64 strains produced biofilm, whereas 34 were @entity10223 -positive, 64 asp-positive and 54 ace-positive. Biofilm production was associated with the presence of @entity10223 (P   <   0.001) and ace genes (P   =   0.021), being higher in infecting (P   <   0.001) and water (P 0.005) isolates as compared with colonizing ones. Clones of environmental water-strains were different than the @entity1 ' clones. The differences found in the incidence of antibiotic resistance, virulence factors and clones suggest that hospital and water enterococci are of different origin.

title: Biofilm synthesis and presence of virulence factors among enterococci isolated from XXXX and water samples.

entities_list: @entity2176 :: ('MESH:D014640', 'Chemical') :: ['vancomycin']

entities_list: @entity797 :: ('1351', 'Species') :: ['Enterococcus faecalis', 'Enterococcus']

entities_list: @entity6375 :: ('1352', 'Species') :: ['Enterococcus faecium']

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: OBJECTIVE: Parametrial involvement (PMI) is one of the most important factors influencing prognosis in locally advanced @entity5 (LACC) @entity1 . We aimed to evaluate PMI rate among LACC @entity1 undergoing neoadjuvant chemotherapy (NACT), thus evaluating the utility of parametrectomy in tailor adjuvant treatments. METHODS: Retrospective evaluation of consecutive 275 @entity1 affected by LACC (IB2-IIB), undergoing NACT followed by type C/class III radical hysterectomy. Basic descriptive statistics, univariate and multivariate analyses were applied in order to identify factors predicting PMI. Survival outcomes were assessed using Kaplan-Meier and Cox models. RESULTS: PMI was detected in 37 (13%) @entity1 : it was associated with vaginal involvement, lymph node positivity and both in 10 (4%), 5 (2%) and 12 (4%) @entity1 , respectively; while PMI alone was observed in only 10 (4%) @entity1 . Among this latter group, adjuvant treatment was delivered in 3 (1%) @entity1 on the basis of pure PMI; while the remaining @entity1 had other characteristics driving adjuvant treatment. Considering factors predicting PMI we observed that only suboptimal pathological responses (OR: 1.11; 95% CI: 1.01, 1.22) and vaginal involvement (OR: 1.29 (95%) CI: 1.17, 1.44) were independently associated with PMI. PMI did not correlate with survival (HR: 2.0; 95% CI: 0.82, 4.89); while clinical response to NACT (HR: 3.35; 95% CI: 1.59, 7.04), vaginal involvement (HR: 2.38; 95% CI: 1.12, 5.02) and lymph nodes positivity (HR: 3.47; 95% CI: 1.62, 7.41), independently correlated with worse survival outcomes. CONCLUSIONS: Our data suggest that PMI had a limited role on the choice to administer adjuvant treatment, thus supporting the potential embrace of less radical surgery in LACC @entity1 undergoing NACT. Further prospective studies are warranted.

title: How often parametrial involvement leads to post-operative adjuvant treatment in locally advanced XXXX after neoadjuvant chemotherapy and type C radical hysterectomy?

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['stage cervical cancer']

answer: @entity5 :: (MESH:D009369,Disease) :: ['cervical cancer']


abstract: Among percutaneous biopsy techniques, the vacuum assisted breast biopsy (VAB) obtains large tissue samples to alleviate some of the limitations associated with conventional percutaneous biopsy techniques. We aimed to determine the efficacy of VAB in previous equivocal biopsies using the mammotome device. MATERIALS AND METHODS: A prospective non-randomized efficacy study was planned and executed on 43 @entity1 (42 @entity1 , 1 @entity1 ) whose previous FNAC and/or CNB of breast masses yielded inconclusive results or were suspicious for @entity5 . RESULTS: VAB revealed @entity5 in 31 (72%) of the 43 @entity1 . Among them, 23 were diagnosed as @entity513 ( @entity513 ) on VAB, 20 underwent surgery and the final histopathological diagnosis was the same in 19 of them. One @entity1 showed @entity513 -in-situ (DCIS) only in the surgical specimen. Other @entity5 included @entity1137 ( @entity1137 ) in 5 @entity1 and one each of DCIS, @entity1893 ( @entity1893 ) and @entity3 from @entity2 . Benign lesions were detected in 12 (28%) @entity1 . These included 8 @entity1557 , 2 @entity3923 and 1 each of @entity1271 and @entity0 . Four @entity1 with @entity1557 underwent surgical excision.

title: Role of directional vacuum assisted breast biopsy in previously equivocal biopsies for breast masses suspicious for XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patient', 'man', 'women', 'patients']

entities_list: @entity1137 :: ('MESH:D018275', 'Disease') :: ['ILC', 'infiltrating lobular carcinoma']

entities_list: @entity0 :: ('MESH:D001943', 'Disease') :: ['breast abscess']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['malignancies', 'cancer', 'malignancy']

entities_list: @entity2 :: ('MESH:D008175', 'Disease') :: ['lung cancer']

entities_list: @entity513 :: ('MESH:D044584', 'Disease') :: ['infiltrative ductal carcinoma', 'IDC', 'ductal carcinoma']

entities_list: @entity3923 :: ('MESH:D005348', 'Disease') :: ['fibrocystic disease']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis']

entities_list: @entity1557 :: ('MESH:D018226', 'Disease') :: ['fibroadenoma', 'fibroadenomas']

entities_list: @entity1893 :: ('MESH:D008228', 'Disease') :: ['non- Hodgkin lymphoma', 'NHL']

answer: @entity5 :: (MESH:D009369,Disease) :: ['malignancy']


abstract: OBJECTIVE: Arterial acute @entity5327 (AAMI) is a vascular and @entity341 , most often surgical, still associated with a poor prognosis and frequent @entity5277 in survivors. We report the results of revascularization in AAMI @entity1 after the creation of an intestinal @entity64 center. METHODS: Since July 2009, we developed a multimodal and multidisciplinary management for AMI, focusing on intestinal viability and involving gastroenterologists, vascular and abdominal surgeons, radiologists, and intensive care specialists. This management was the first step to the creation of an intestinal @entity64 center, based on the @entity64 unit model. All @entity1 received: (1) a specific medical protocol; (2) endovascular and/or open surgical revascularization whenever possible; and/or (3) resection of non-viable small bowel. We aimed to study survival, morbidity, type of revascularization, and bowel resection in @entity1 who benefited from arterial revascularization in our intestinal @entity64 center. RESULTS: Eighty-three @entity1 with AMI were prospectively enrolled in the intestinal @entity64 center. Among them, 29 @entity1 with AAMI underwent revascularization. The mean age was 50.2     12  years, with 41% of male gender. The mean follow-up was 22.7     19  months. Overall 2-year survival was 89.2%, and 30-day operative mortality was 6.9%. Surgical revascularization included bypass grafting (65%), endarterectomy with patch angioplasty (21%)     retrograde open mesenteric stenting of the superior mesenteric artery (7%), and endovascular revascularization as first stage procedure (38%). The 2-year primary patency rate of open revascularization was 88%. The rate and the median length of bowel resected were 24% and 43  cm (range, 36-49  cm), respectively. CONCLUSIONS: In our experience, revascularization of AAMI @entity1 as part of a multidisciplinary and multimodal management leads to encouraging results. Vascular surgeons have a central role in a dedicated intestinal @entity64 center.

title: Revascularization of acute XXXX after creation of a dedicated multidisciplinary center.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity341 :: ('MESH:D004630', 'Disease') :: ['gastroenterologic emergency']

entities_list: @entity5277 :: ('MESH:D012778', 'Disease') :: ['short bowel syndrome']

entities_list: @entity5327 :: ('MESH:D065666', 'Disease') :: ['mesenteric ischemia']

answer: @entity5327 :: (MESH:D065666,Disease) :: ['mesenteric ischemia']


abstract: BACKGROUND AND PURPOSE: @entity428 ( @entity428 ) control is a therapeutic target in @entity1 with @entity510 , although only a limited number of studies assessed its course and effect on outcome. Pressure-time dose (PTDICP) is a method to quantify the burden and the time spent above a defined threshold of @entity428 . PTDICP or its relationship with outcome has never been evaluated in @entity510 . METHODS: Analysis of data prospectively collected from @entity510 @entity1 admitted to Neurointensive Care Unit. Monitored data, including @entity428 , were digitally recorded minute-by-minute in the first 7 days. PTDICP (mm Hg h) was computed using 4 predefined thresholds (15, 20, 25, and 30 mm Hg). Outcome was assessed through Extended Glasgow Outcome Scale at hospital discharge and at 6 months. RESULTS: Fifty-five @entity1 were enrolled. Forty-two @entity1 (76%) presented with a poor clinical grade. Overall, mortality was 17% at hospital discharge and 34% at 6 months. Half of @entity1 required extensive therapy to control high @entity428 during day 1. Median @entity428 was 10 mm Hg (4-75), whereas median PTDICP15, PTDICP20, PTDICP25, PTDICP30 were, respectively, 13, 4, 2, and 1 mm Hg h. We observed an association between mortality at hospital discharge and higher level of PTDICP using 20, 25, and 30 mm Hg as thresholds and between exposure to a moderate-level PTDICP30 and unfavorable long-term outcome. CONCLUSIONS: PTDICP may better define one of the insults that the brain suffers after @entity1756 , and exposure to moderate PTDICP30 was significant prognostic factor of 6-month unfavorable outcome.

title: High-Resolution Intracranial Pressure Burden and Outcome in XXXX .

entities_list: @entity510 :: ('MESH:D013345', 'Disease') :: ['aneurysmal subarachnoid hemorrhage']

entities_list: @entity1756 :: ('MESH:D017542', 'Disease') :: ['aneurysmal rupture']

entities_list: @entity428 :: ('MESH:D019586', 'Disease') :: ['Intracranial pressure', 'ICP', 'intraparenchymal ICP']

answer: @entity510 :: (MESH:D013345,Disease) :: ['Subarachnoid Hemorrhage']


abstract: BACKGROUND: Epigenetic adjustments of the chromatin architecture through histone modifications are reactive to the environment and can establish chromatin states which are permissive or repressive to gene expression. Epigenetic regulation of gene expression is cell specific and therefore, it is important to understand its contribution to individual cellular responses in tissues like the airway epithelium which forms the mucosal barrier to the inhaled environment within the lung. The airway epithelium of @entity748 is abnormal with dysregulation of genes such as @entity470 ( @entity470 ), the   N isoform of the transcription factor @entity4206 (  Np63), and @entity8850 ( @entity8850 ), integral to differentiation, proliferation, and @entity32 . It is important to establish in diseases like @entity565 how histone modifications affect tissue responses such as proliferation and differentiation. OBJECTIVES: To characterize the global histone acetylation and methylation status in the epithelium of @entity748 compared to healthy subjects and to identify the impact of these variations on genes involved in epithelial functions. METHODS: Whole lungs were obtained from healthy and @entity748 subjects (n   =   6) from which airway epithelial cells (AECs) were isolated and airway sections were taken for analysis of histone @entity376 acetylation and methylation by immunohistochemistry. AECs were subjected to chromatin immunoprecipitation (ChIP) using anti-H3K18ac and anti-H3K4me2 antibodies followed by RT-PCR targeting   Np63, @entity470 , and @entity8850 . AECs were also treated with @entity10319 and changes in   Np63, @entity470 , and @entity8850 expression were determined. RESULTS: We identified an increase in the acetylation of @entity376 18 on histone 3 (H3K18ac) and trimethylation of @entity376 9 on histone 3 (H3K9me3) in the airway epithelium of @entity748 compared to healthy subjects. We found increased association of H3K18ac around the transcription start site of   Np63, @entity470 , and @entity8850 in AECs of @entity748 . However, we were unable to modify the expression of these genes with the use of the HDAC inhibitor @entity10319 in healthy subjects. DISCUSSION: The airway epithelium from @entity748 subjects displays increased acetylation of H3K18 and association of this mark around the transcription start site of   Np63, @entity470 , and @entity8850 . These findings suggest a complex interaction between histone modifications and gene regulation in @entity565 .

title: Elevated H3K18 acetylation in airway epithelial cells of XXXX subjects.

entities_list: @entity748 :: ('MESH:D013224', 'Disease') :: ['asthmatic', 'asthmatics']

entities_list: @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation']

entities_list: @entity8850 :: ('6778', 'Gene') :: ['signal transducer and activator of transcription 6', 'STAT6']

entities_list: @entity470 :: ('1956', 'Gene') :: ['EGFR', 'epidermal growth factor receptor']

entities_list: @entity376 :: ('CHEBI:25094', 'Chemical') :: ['lysine']

answer: @entity748 :: (MESH:D013224,Disease) :: ['asthmatic']


abstract: PURPOSE: @entity1313 survivors have increased risk of @entity25 , particularly @entity25 ( @entity25 ). Few studies have examined @entity25 in this population. METHODS: 153 @entity1 and adolescents ages 8-18 and their parents completed questionnaires (Modified Epworth Sleepiness Scale, Kosair @entity1 's Hospital Sleep Questionnaire, @entity1 's Report of Sleep Patterns, @entity1 's Sleep Hygiene Scale) during clinic visits. @entity1 were at least 5  years from diagnosis and 2  years post-treatment. Group differences in age at diagnosis, body mass index, type of treatment received, and @entity5 location were examined. RESULTS: One-third of adolescents and one-fifth of @entity1 reported @entity25 . @entity1 and parents had fair concordance (kappa coefficient   =   .64) in their report of @entity25 , while adolescents and parents had poor concordance (kappa coefficient   =   .37). Per parents, most @entity1 slept 8 to 9  h per night. Poor bedtime routines were reported for @entity1 , while adolescents endorsed poor sleep stability. Extended weekend sleep was reported across age groups. A BMI in the @entity28 range was related to higher parent-reported @entity25 in @entity1 . @entity25 @entity1353 was associated with elevated BMI in adolescents. CONCLUSIONS: While survivors reported achieving recommended amounts of sleep each night, 20 to 30  % reported @entity25 . Poor concordance among parent and adolescent report highlights the importance of obtaining self-report when assessing sleep concerns. Obesity is a modifiable factor in reducing symptoms of @entity25 in this population. Finally, the lack of association between @entity25 and @entity1313 location, BMI, or treatment received was unexpected and warrants further investigation.

title: Sleep complaints in survivors of pediatric XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'Children', 'Participants']

entities_list: @entity1313 :: ('MESH:D001932', 'Disease') :: ['brain tumor', 'Pediatric brain tumor']

entities_list: @entity1353 :: ('MESH:D004417', 'Disease') :: ['breathing']

entities_list: @entity25 :: ('MESH:D012893', 'Disease') :: ['sleep problems', 'Sleep-disordered', 'sleep disturbances', 'excessive daytime sleepiness', 'EDS']

answer: @entity1313 :: (MESH:D001932,Disease) :: ['brain tumors']


abstract: BACKGROUND: @entity14756 ( @entity20117 ) is usually characterised by a progressive @entity1897 often with associated @entity712 and is due to dominantly inherited transthyretin mutations causing accelerated @entity527 . The UK population is unique in that the majority of @entity1 have the @entity72158 missense mutation in @entity20117 where @entity4149 is replaced by @entity5536 at position 60. This has been traced to a single founder mutation from north-west Ireland. The @entity16 phenotype is less well described than the cardiac manifestations in this group. METHODS: We present the findings from an observational cohort study of @entity1 with @entity20117 attending the National @entity74 Clinic between 2009 and 2013. Detailed clinical neurological and electrophysiological data were collected on all @entity1 alongside correlating autonomic and cardiac assessments. Follow-up data were available on a subset. RESULTS: Forty-four @entity1 with genetically confirmed @entity20117 were assessed; 37 were symptomatic; mean age at onset=62 years, range=38-75 years; 75.7% male. @entity72158 was the most common mutation (17/37), followed by @entity21559 (5/37). A severe, rapidly progressive, predominantly length dependent @entity16 was the predominant phenotype. @entity72158 @entity1 were distinguished by earlier and more frequent association with @entity923 ; a predominance of negative sensory symptoms at onset; significant @entity10795 ; and a non-length dependent progression of @entity51 . @entity16 was observed over a relatively short follow-up period (2 years) in 20 @entity1 with evidence of clinically measurable annual change in Medical Research Council (MRC) sum score (-1.5 points per year) and Charcot Marie Tooth @entity16 Score (CMTNS:2.7 points per year), and a congruent trend in the electrophysiological measures used. CONCLUSION: The description of the @entity20117 @entity16 phenotype, especially in the @entity72158 @entity1 , should aid early diagnosis as well as contribute to the understanding of its natural history.

title: A study of the XXXX associated with transthyretin amyloidosis ( @entity20117 ) in the UK.

entities_list: @entity712 :: ('MESH:D006333', 'Disease') :: ['cardiac failure']

entities_list: @entity527 :: ('MESH:D058225', 'Disease') :: ['amyloid deposition']

entities_list: @entity21559 :: ('p|SUB|V|30|M', 'ProteinMutation') :: ['V30M']

entities_list: @entity16 :: ('MESH:D009422', 'Disease') :: ['Neuropathy', 'axonal sensorimotor neuropathy', 'Progression of the neuropathy', 'neuropathy']

entities_list: @entity1897 :: ('MESH:D010523', 'Disease') :: ['peripheral and autonomic neuropathy']

entities_list: @entity51 :: ('MESH:D009461', 'Disease') :: ['motor deficit']

entities_list: @entity10795 :: ('MESH:D053421', 'Disease') :: ['vibration deficits']

entities_list: @entity74 :: ('MESH:D030342', 'Disease') :: ['Hospital Inherited Neuropathy']

entities_list: @entity923 :: ('MESH:D002349', 'Disease') :: ['carpal tunnel syndrome']

entities_list: @entity14756 :: ('MESH:D028226', 'Disease') :: ['Hereditary transthyretin amyloidosis']

answer: @entity16 :: (MESH:D009422,Disease) :: ['neuropathy']


abstract: BACKGROUND: @entity14756 ( @entity20117 ) is usually characterised by a progressive @entity1897 often with associated @entity712 and is due to dominantly inherited transthyretin mutations causing accelerated @entity527 . The UK population is unique in that the majority of @entity1 have the @entity72158 missense mutation in @entity20117 where @entity4149 is replaced by @entity5536 at position 60. This has been traced to a single founder mutation from north-west Ireland. The @entity16 phenotype is less well described than the cardiac manifestations in this group. METHODS: We present the findings from an observational cohort study of @entity1 with @entity20117 attending the National @entity74 Clinic between 2009 and 2013. Detailed clinical neurological and electrophysiological data were collected on all @entity1 alongside correlating autonomic and cardiac assessments. Follow-up data were available on a subset. RESULTS: Forty-four @entity1 with genetically confirmed @entity20117 were assessed; 37 were symptomatic; mean age at onset=62 years, range=38-75 years; 75.7% male. @entity72158 was the most common mutation (17/37), followed by @entity21559 (5/37). A severe, rapidly progressive, predominantly length dependent @entity16 was the predominant phenotype. @entity72158 @entity1 were distinguished by earlier and more frequent association with @entity923 ; a predominance of negative sensory symptoms at onset; significant @entity10795 ; and a non-length dependent progression of @entity51 . @entity16 was observed over a relatively short follow-up period (2 years) in 20 @entity1 with evidence of clinically measurable annual change in Medical Research Council (MRC) sum score (-1.5 points per year) and Charcot Marie Tooth @entity16 Score (CMTNS:2.7 points per year), and a congruent trend in the electrophysiological measures used. CONCLUSION: The description of the @entity20117 @entity16 phenotype, especially in the @entity72158 @entity1 , should aid early diagnosis as well as contribute to the understanding of its natural history.

title: A study of the @entity16 associated with transthyretin amyloidosis ( XXXX ) in the UK.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

answer: @entity20117 :: (7276,Gene) :: ['ATTR']


abstract: Mono- and bi-allelic mutations in the @entity8950 ( @entity8950 ) may cause @entity2525 , autosomal dominant and recessive exudative @entity11810 , or @entity22933 ( @entity22933 ). We report on a @entity1 affected with @entity22933 and carrying compound mutations. The father carried the splice mutation and suffered from severe @entity79 since childhood. The mother carried the missense mutation without any clinical manifestations. The genetic diagnosis of their @entity1 allowed for appropriate treatment in the father and for the detection of @entity2331 in the mother. Mono- and bi-allelic mutations in @entity8950 may cause @entity2525 , autosomal dominant and recessive exudative @entity11810 , or @entity22933 . @entity22933 is a component of persistent fetal vasculature of the eye, characterized by highly variable expressivity and resulting in a wide spectrum of anterior and/or posterior @entity245 , which may lead to @entity1939 . We evaluated a family diagnosed with @entity22933 in their only @entity1 . The @entity1 presented @entity3917 during the first 3  weeks of life, followed by leukocoria at 2  months of age. Molecular resequencing of @entity48178 , @entity13034 , and @entity8950 was performed in the @entity1 and segregation of the observed mutations in the parents. At presentation, fundus examination of the @entity1 showed a retrolental mass in the right eye. Ultrasonography revealed @entity1713 in both eyes. Thorough familial analysis revealed that the father suffered from many @entity174 since childhood without specific @entity79 , treatment, or management. The mother was asymptomatic. Molecular analysis in the proband identified two mutations: a @entity72159 splice mutation and @entity72160 missense mutation. We report the case of a @entity1 affected with @entity22933 and carrying compound heterozygous @entity8950 mutations. This genetic diagnosis allowed the clinical diagnosis of the bone problem to be made in the father, resulting in better management of the family. It also enabled preventive treatment to be prescribed for the mother and accurate genetic counseling to be provided.

title: XXXX in @entity1 of @entity1 with hereditary bone disease.

entities_list: @entity22933 :: ('MESH:D054514', 'Disease') :: ['persistent hyperplastic primary vitreous', 'PHPV']

entities_list: @entity11810 :: ('MESH:C537700', 'Disease') :: ['vitreoretinopathy, juvenile osteoporosis']

entities_list: @entity174 :: ('MESH:D050723', 'Disease') :: ['fractures']

entities_list: @entity1713 :: ('MESH:D012163', 'Disease') :: ['retinal detachment']

entities_list: @entity245 :: ('MESH:D002658', 'Disease') :: ['congenital developmental defects']

entities_list: @entity8950 :: ('4041', 'Gene') :: ['low-density lipoprotein receptor related protein 5', 'LRP5']

entities_list: @entity1939 :: ('MESH:D001766', 'Disease') :: ['blindness']

entities_list: @entity79 :: ('MESH:D001847', 'Disease') :: ['fragility bone diagnosis', 'bone fragility']

entities_list: @entity2331 :: ('MESH:D001851', 'Disease') :: ['osteopenia']

entities_list: @entity3917 :: ('MESH:D020795', 'Disease') :: ['photophobia']

entities_list: @entity2525 :: ('MESH:D010022', 'Disease') :: ['osteopetrosis']

answer: @entity1939 :: (MESH:D001766,Disease) :: ['Potential blindness']


abstract: Mono- and bi-allelic mutations in the @entity8950 ( @entity8950 ) may cause @entity2525 , autosomal dominant and recessive exudative @entity11810 , or @entity22933 ( @entity22933 ). We report on a @entity1 affected with @entity22933 and carrying compound mutations. The father carried the splice mutation and suffered from severe @entity79 since childhood. The mother carried the missense mutation without any clinical manifestations. The genetic diagnosis of their @entity1 allowed for appropriate treatment in the father and for the detection of @entity2331 in the mother. Mono- and bi-allelic mutations in @entity8950 may cause @entity2525 , autosomal dominant and recessive exudative @entity11810 , or @entity22933 . @entity22933 is a component of persistent fetal vasculature of the eye, characterized by highly variable expressivity and resulting in a wide spectrum of anterior and/or posterior @entity245 , which may lead to @entity1939 . We evaluated a family diagnosed with @entity22933 in their only @entity1 . The @entity1 presented @entity3917 during the first 3  weeks of life, followed by leukocoria at 2  months of age. Molecular resequencing of @entity48178 , @entity13034 , and @entity8950 was performed in the @entity1 and segregation of the observed mutations in the parents. At presentation, fundus examination of the @entity1 showed a retrolental mass in the right eye. Ultrasonography revealed @entity1713 in both eyes. Thorough familial analysis revealed that the father suffered from many @entity174 since childhood without specific @entity79 , treatment, or management. The mother was asymptomatic. Molecular analysis in the proband identified two mutations: a @entity72159 splice mutation and @entity72160 missense mutation. We report the case of a @entity1 affected with @entity22933 and carrying compound heterozygous @entity8950 mutations. This genetic diagnosis allowed the clinical diagnosis of the bone problem to be made in the father, resulting in better management of the family. It also enabled preventive treatment to be prescribed for the mother and accurate genetic counseling to be provided.

title: @entity1939 in XXXX of @entity1 with hereditary bone disease.

answer: @entity1 :: (9606,Species) :: ['children']


abstract: Mono- and bi-allelic mutations in the @entity8950 ( @entity8950 ) may cause @entity2525 , autosomal dominant and recessive exudative @entity11810 , or @entity22933 ( @entity22933 ). We report on a @entity1 affected with @entity22933 and carrying compound mutations. The father carried the splice mutation and suffered from severe @entity79 since childhood. The mother carried the missense mutation without any clinical manifestations. The genetic diagnosis of their @entity1 allowed for appropriate treatment in the father and for the detection of @entity2331 in the mother. Mono- and bi-allelic mutations in @entity8950 may cause @entity2525 , autosomal dominant and recessive exudative @entity11810 , or @entity22933 . @entity22933 is a component of persistent fetal vasculature of the eye, characterized by highly variable expressivity and resulting in a wide spectrum of anterior and/or posterior @entity245 , which may lead to @entity1939 . We evaluated a family diagnosed with @entity22933 in their only @entity1 . The @entity1 presented @entity3917 during the first 3  weeks of life, followed by leukocoria at 2  months of age. Molecular resequencing of @entity48178 , @entity13034 , and @entity8950 was performed in the @entity1 and segregation of the observed mutations in the parents. At presentation, fundus examination of the @entity1 showed a retrolental mass in the right eye. Ultrasonography revealed @entity1713 in both eyes. Thorough familial analysis revealed that the father suffered from many @entity174 since childhood without specific @entity79 , treatment, or management. The mother was asymptomatic. Molecular analysis in the proband identified two mutations: a @entity72159 splice mutation and @entity72160 missense mutation. We report the case of a @entity1 affected with @entity22933 and carrying compound heterozygous @entity8950 mutations. This genetic diagnosis allowed the clinical diagnosis of the bone problem to be made in the father, resulting in better management of the family. It also enabled preventive treatment to be prescribed for the mother and accurate genetic counseling to be provided.

title: @entity1939 in @entity1 of XXXX with hereditary bone disease.

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: BACKGROUND: The association of @entity4032 with @entity717 is well described. However debate exists with regard optimal management notably should 'asymptomatic' @entity717 undergo operation? The present study therefore sought to determine: (1) the risk(s) of @entity3313 in @entity1 diagnosed with @entity4032 and (2) define morbidity associated with operation for ' @entity10094 in a fragile @entity1 cohort with co-existent @entity299 . METHODS: Medical case record reviews of @entity981 @entity1 born during January 1993-December 2013 and attending a UK paediatric centre were analyzed. RESULTS: Of a total of 92 @entity1 , 16 (17.4%) cases underwent foregut imaging studies. Three examinations were performed in 'symptomatic' @entity1 . Twelve studies reported 'abnormal anatomy' with only five @entity1 undergoing surgical correction. No complication(s) were recorded after Ladd's operation to correct defects. A single fatality occurred within 30 days postoperatively from @entity712 . In 87 @entity1 in whom Ladd's operation was not undertaken, no single @entity1 developed @entity3313 (median length of follow-up 27.2 months, total 446.1 @entity1 years). CONCLUSION: This study strongly supports a 'watchful waiting' policy for @entity4032 @entity1 . Many @entity1 who ultimately die from @entity299 may avoid unnecessary abdominal surgery.

title: Heterotaxy and XXXX : 20 years experience at a UK regional paediatric surgery centre.

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'patients', 'patient', 'person']

entities_list: @entity717 :: ('MESH:D009069', 'Disease') :: ['bowel rotation anomalies', 'intestinal rotation anomalies']

entities_list: @entity981 :: ('MESH:D054198', 'Disease') :: ['ALL heterotaxy']

entities_list: @entity712 :: ('MESH:D006333', 'Disease') :: ['cardiac failure']

entities_list: @entity3313 :: ('MESH:D045822', 'Disease') :: ['intestinal volvulus', 'volvulus']

entities_list: @entity10094 :: ('MESH:D058070', 'Disease') :: ["asymptomatic' anomalies"]

entities_list: @entity299 :: ('MESH:D006331', 'Disease') :: ['congenital heart disease', 'heart disease']

entities_list: @entity4032 :: ('MESH:D059446', 'Disease') :: ['heterotaxy']

answer: @entity717 :: (MESH:D009069,Disease) :: ['intestinal rotation anomalies']


abstract: INTRODUCTION: Pathological bone changes differ considerably between inflammatory arthritic diseases and most studies have focused on @entity79 . @entity1753 ( @entity1753 ) is a model for @entity309 , which, in addition to @entity79 , demonstrates bone formation at the time of clinical manifestations. The objective of this study was to use this model to characterise the histological and molecular changes in bone remodelling, and relate these to the clinical disease development. METHODS: A histological and gene expression profiling time-course study on bone remodelling in @entity1753 was linked to onset of clinical symptoms. Global gene expression was studied with a gene chip array system. RESULTS: The main histopathological changes in bone structure and @entity32 occurred during the first two weeks following the onset of clinical symptoms in the joint. Hereafter, the @entity32 declined and remodelling of formed bone dominated. Global gene expression profiling showed simultaneous upregulation of genes related to bone changes and @entity32 in week 0 to 2 after onset of clinical disease. Furthermore, we observed time-dependent expression of genes involved in early and late osteoblast differentiation and function, which mirrored the histopathological bone changes. The differentially expressed genes belong to the bone morphogenetic pathway ( @entity6861 ) and, in addition, include the osteoblast markers @entity16240 ( @entity16240 ), bone @entity16699 protein (Bglap1), and @entity1096 ( @entity1096 ). Pregnancy-associated protein A ( @entity15714 ) and @entity12635 ( @entity12635 ), differentially expressed in the early disease phase, are proposed to participate in bone formation, and we suggest that they play a role in early bone formation in the @entity1753 model. Comparison to @entity1 genome-wide association studies (GWAS) revealed differential expression of several genes associated with @entity1 @entity625 . CONCLUSIONS: In the @entity1753 model, bone formation in the joint starts shortly after onset of clinical symptoms, which results in bony fusion within one to two weeks. This makes it a candidate model for investigating the relationship between @entity32 and bone formation in @entity625 .

title: Kinetics of gene expression and bone remodelling in the clinical phase of collagen-induced XXXX .

entities_list: @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation']

entities_list: @entity625 :: ('MESH:D001168', 'Disease') :: ['arthritis', 'inflammatory arthritis']

entities_list: @entity309 :: ('MESH:D001172', 'Disease') :: ['rheumatoid arthritis']

entities_list: @entity16240 :: ('3381', 'Gene') :: ['integrin-binding sialoprotein', 'Ibsp']

entities_list: @entity1753 :: ('MESH:D001169', 'Disease') :: ['Collagen-induced arthritis', 'CIA']

entities_list: @entity79 :: ('MESH:D001847', 'Disease') :: ['bone erosion']

entities_list: @entity16699 :: ('MESH:D015055', 'Chemical') :: ['gamma-carboxyglutamate']

entities_list: @entity1096 :: ('6696', 'Gene') :: ['secreted phosphoprotein 1', 'Spp1']

answer: @entity625 :: (MESH:D001168,Disease) :: ['arthritis']


abstract: OBJECTIVE: To report the feasibility, safety, and clinical outcomes of an exploratory study of MR-guided Laser Interstitial Thermal Therapy (MRgLITT) as a minimally invasive surgical procedure for the ablation of epileptogenic foci in @entity1 with drug-resistant, lesional @entity302 . METHODS: Retrospective chart review of all MRgLITT procedures at a single tertiary care center. All procedures were performed using a U.S. Food and Drug Administration (FDA)-cleared surgical laser ablation system (Visualase Thermal Therapy System). Predefined clinical and surgical variables were extracted from archived medical records. RESULTS: Seventeen @entity1 underwent 19 MRgLITT procedures from May 2011 to January 2014. Mean age at @entity410 onset was 7.1  years (range 0.1-14.8  years). Mean age at surgery was 15.3  years (range 5.9-20.6  years). Surgical substrates were mixed but mainly composed of focal cortical @entity1141 (n  =  11). Complications occurred in four @entity1 . Average length of hospitalization postsurgery was 1.56  days. Mean follow-up was 16.1  months (n  =  16; range 3.5-35.9  months). Engel class I outcome was achieved in seven @entity1 (7/17; 41%), Engel class II in one (1/17; 6%), Engel class III in three (3/17; 18%), and Engel class IV in six (6/17; 35%). Three @entity1 (3/8; 38%) with class I and II outcomes and five @entity1 (5/9; 56%) with class III and IV outcomes had at least one prior resection. Fisher's exact test was not statistically significant for the association between Engel class outcome and previous resection (p  =  0.64). SIGNIFICANCE: This study provides descriptive results regarding the use of MRgLITT in a mixed population of pediatric, lesional, drug-resistant @entity302 cases. The ability to classify case-specific outcomes and reduce technical complications is anticipated as experience develops. Further multicenter, prospective studies are required to delineate optimal candidates for MRgLITT, and larger cohorts are needed to more accurately define outcome and complication rates.

title: MR-guided laser interstitial thermal therapy for pediatric drug-resistant lesional XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'patients']

entities_list: @entity302 :: ('MESH:D004827', 'Disease') :: ['epilepsy']

entities_list: @entity1141 :: ('MESH:C535662', 'Disease') :: ['dysplasia']

answer: @entity302 :: (MESH:D004827,Disease) :: ['epilepsy']


abstract: PURPOSE: The objective of this study is to characterize the impact of exposure to cryoprotectants followed by vitrification on primordial follicle survival and activation using a fetal @entity291 model. METHODS: In the first study, fetal @entity291 cortical pieces were exposed to cryoprotectants with or without @entity969 and cultured up to 7  days in the presence or absence of @entity8788 . In the second study, cortical pieces were exposed to cryoprotectants with or without @entity969 , vitrified, and cultured up to 7  days after warming in the presence or absence of @entity8788 . Viability and morphology of follicles, as well as proliferation and/or DNA repair in ovarian tissue were analyzed. RESULTS: When compared to non-exposed controls, normal follicular morphology was affected in groups exposed to cryoprotectants only immediately post-exposure and after 1  day of culture, but improved by day 3 and did not significantly differ by day 7. Similarly, normal follicular morphology was compromised in vitrified groups after warming and on day 1 compared to controls, but improved by days 3 and 7. Proliferation and/or DNA repair in ovarian tissue was not affected by vitrification in this model. Cryoprotectant exposure and vitrification of ovarian tissue did not impair the activation of primordial follicles in response to @entity8788 , although activation was delayed relative to non-exposed controls. Interestingly, @entity969 had no noticeable protective effect. CONCLUSION: Vitrified fetal @entity291 ovarian tissue has the intrinsic capacity to mitigate the immediate damage to primordial follicles' morphology and retains the capacity to activate. These findings provide a basis for a successful cryopreservation protocol for ovarian cortical tissue in other species including @entity1 .

title: Damage to fetal XXXX ovarian tissue caused by cryoprotectant exposure and vitrification is mitigated during tissue culture.

entities_list: @entity969 :: ('MESH:D013395', 'Chemical') :: ['sucrose']

answer: @entity291 :: (9913,Species) :: ['bovine']


abstract: INTRODUCTION: Gout is a chronic @entity32 the development of which is associated with @entity28 -induced @entity209 . However, a substantial number of @entity28 @entity1 (body mass index [BMI] <25  kg/m(2)) also develop @entity210 in Korea. It was suggested that accumulation of visceral fat rather than subcutaneous fat is associated with @entity209 and @entity5052 in @entity1 with @entity210 ; therefore, we hypothesized that visceral fat accumulation was @entity28 @entity1 . METHODS: One hundred and three male @entity1 with @entity210 and 204 age-matched healthy controls who attended a health check-up examination were recruited after the review of medical charts. The visceral fat area (VFA) was measured using the bioelectrical impedance analysis (BIA) method, and a VFA >100  cm(2) was defined as visceral fat @entity28 (VFO). The frequency of VFO was compared in @entity1 and control groups. The frequencies of @entity209 and related parameters were also investigated. RESULTS: BMI, waist circumference, total fat mass, serum @entity1674 , and serum @entity413 levels were significantly greater in @entity1 compared with controls. VFA and the prevalence of VFO was increased in @entity210 @entity1 compared with controls. There were positive correlations between VFA and serum @entity412 levels and serum @entity413 levels. Multivariate regression analysis revealed that VFO is an independent risk factor for @entity210 (odds ratio 2.488, 95% confidence interval 1.041-4.435). In @entity28 subgroup analyses ( @entity210 @entity1 , n   =   38; healthy controls, n   =   150), VFA (98.7        19.3 vs. 91.0        16.7, P   =   0.016) and the frequency of VFO (47.4 vs. 27.3%, P   =   0.017) remained significantly higher in @entity210 @entity1 . There was no difference in either BMI or total fat mass between @entity1 and controls in the @entity28 subgroup. The prevalence of @entity209 in @entity1 with @entity210 was 31.7% (33/104), compared with 13.2% (5/38) in the @entity28 subgroup according to modified ATP III criteria. CONCLUSION: VFO, measured using BIA, is observed more frequently in @entity1 with @entity210 compared with healthy controls, even in @entity28 individuals. Therefore, VFO might more properly represent metabolic derangements in @entity1 with @entity28 .

title: Visceral fat XXXX is highly associated with @entity210 in a metabolically obese but normal weighted population: a case control study.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammatory disease']

entities_list: @entity28 :: ('MESH:D009765', 'Disease') :: ['gout than general obesity', 'obesity', 'increased in non-obese gout', 'non-obese']

entities_list: @entity1674 :: ('MESH:D014280', 'Chemical') :: ['triglycerides']

entities_list: @entity412 :: ('CHEBI:17855', 'Chemical') :: ['triglyceride']

entities_list: @entity5052 :: ('MESH:D033461', 'Disease') :: ['hyperuricemia']

entities_list: @entity209 :: ('MESH:D008659', 'Disease') :: ['metabolic syndrome', 'metabolic abnormalities']

entities_list: @entity210 :: ('MESH:D006073', 'Disease') :: ['gout', 'primary gout']

entities_list: @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose']

answer: @entity28 :: (MESH:D009765,Disease) :: ['obesity']


abstract: INTRODUCTION: Gout is a chronic @entity32 the development of which is associated with @entity28 -induced @entity209 . However, a substantial number of @entity28 @entity1 (body mass index [BMI] <25  kg/m(2)) also develop @entity210 in Korea. It was suggested that accumulation of visceral fat rather than subcutaneous fat is associated with @entity209 and @entity5052 in @entity1 with @entity210 ; therefore, we hypothesized that visceral fat accumulation was @entity28 @entity1 . METHODS: One hundred and three male @entity1 with @entity210 and 204 age-matched healthy controls who attended a health check-up examination were recruited after the review of medical charts. The visceral fat area (VFA) was measured using the bioelectrical impedance analysis (BIA) method, and a VFA >100  cm(2) was defined as visceral fat @entity28 (VFO). The frequency of VFO was compared in @entity1 and control groups. The frequencies of @entity209 and related parameters were also investigated. RESULTS: BMI, waist circumference, total fat mass, serum @entity1674 , and serum @entity413 levels were significantly greater in @entity1 compared with controls. VFA and the prevalence of VFO was increased in @entity210 @entity1 compared with controls. There were positive correlations between VFA and serum @entity412 levels and serum @entity413 levels. Multivariate regression analysis revealed that VFO is an independent risk factor for @entity210 (odds ratio 2.488, 95% confidence interval 1.041-4.435). In @entity28 subgroup analyses ( @entity210 @entity1 , n   =   38; healthy controls, n   =   150), VFA (98.7        19.3 vs. 91.0        16.7, P   =   0.016) and the frequency of VFO (47.4 vs. 27.3%, P   =   0.017) remained significantly higher in @entity210 @entity1 . There was no difference in either BMI or total fat mass between @entity1 and controls in the @entity28 subgroup. The prevalence of @entity209 in @entity1 with @entity210 was 31.7% (33/104), compared with 13.2% (5/38) in the @entity28 subgroup according to modified ATP III criteria. CONCLUSION: VFO, measured using BIA, is observed more frequently in @entity1 with @entity210 compared with healthy controls, even in @entity28 individuals. Therefore, VFO might more properly represent metabolic derangements in @entity1 with @entity28 .

title: Visceral fat @entity28 is highly associated with XXXX in a metabolically obese but normal weighted population: a case control study.

answer: @entity210 :: (MESH:D006073,Disease) :: ['primary gout']


abstract: BACKGROUND: We describe our experiences with vaginal vault resection for vaginal recurrence of @entity5 after hysterectomy and radiotherapy. After operative treatment, the rate of vaginal vault recurrence of uterine @entity5 is reported to be about 5%. There is no consensus regarding the treatment for these cases. METHODS: Between 2004 and 2012, eight @entity1 with vaginal vault recurrence underwent removal of the vaginal wall via laparotomy after hysterectomy and radiotherapy. RESULTS: The median @entity1 age was 45 years (range 35 to 70 years). The median operation time was 244.5 min (range 172 to 590 min), the median estimated @entity190 was 362.5 mL (range 49 to 1,890 mL), and the median duration of hospitalization was 24.5 days (range 11 to 50 days). Two @entity1 had intraoperative complications: a grade 1 @entity130 and a grade 1 @entity1494 . The following postoperative complications were observed: one @entity1 had @entity3556 , three @entity1 developed vesicovaginal fistulae, and one @entity1 had repeated ileus. Two @entity1 needed clean intermittent catheterization. Local control was achieved in five of the eight cases. CONCLUSIONS: Vaginal vault resection is an effective treatment for vaginal recurrence of @entity5 after hysterectomy and radiotherapy. However, complications of this procedure can be expected to reduce quality of life. Therefore, this operation should be selected with great care.

title: Resection of the vaginal vault for vaginal recurrence of XXXX after hysterectomy and brachytherapy.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity3556 :: ('MESH:D014592', 'Disease') :: ['vaginal vault bleeding']

entities_list: @entity1494 :: ('MESH:D001745', 'Disease') :: ['bladder injury']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cervical cancer']

entities_list: @entity190 :: ('MESH:D006473', 'Disease') :: ['blood loss']

entities_list: @entity130 :: ('MESH:D014947', 'Disease') :: ['bowel injury']

answer: @entity5 :: (MESH:D009369,Disease) :: ['cervical cancer']


abstract: Development of biodegradable composites having the ability to suppress or eliminate the pathogenic micro-biota or modulate the inflammatory response has attracted great interest in order to limit/repair periodontal tissue destruction. The present report includes the development of non-steroidal anti-inflammatory drug encapsulated novel biodegradable chitosan (CS)/ @entity4832 (PVA)/ @entity692 (HA) electro-spun (e-spun) composite nanofibrous mats and films and study of the effect of heat treatment on fibers and films morphology. It also describes comparative in-vitro drug release profiles from heat treated and control (non-heat treated) nanofibrous mats and films containing varying concentrations of @entity5230 (PX). Electrospinning was used to obtain drug loaded ultrafine fibrous mats. The physical/chemical interactions were evaluated by Fourier Transform Infrared (FT-IR) spectroscopy. The morphology, structure and pore size of the materials were investigated by @entity4653 ( @entity4653 ). The thermal behavior of the materials was investigated by thermal gravimetric analysis (TGA) and differential scanning calorimetry (DSC). Control (not heat treated) and heat treated e-spun fibers mats and films were tested for in vitro drug release studies at physiological pH7.4 and initially, as per requirement burst release patterns were observed from both fibers and films and later sustained release profiles were noted. In vitro cytocompatibility was performed using VERO cell line of epithelial cells and all the synthesized materials were found to be non-cytotoxic. The current observations suggested that these materials are potential candidates for periodontal regeneration.

title: Synthesis of XXXX loaded novel electrospun biodegradable nanocomposite scaffolds for periodontal regeneration.

entities_list: @entity692 :: ('MESH:D017886', 'Chemical') :: ['hydroxyapatite']

entities_list: @entity5230 :: ('MESH:D010894', 'Chemical') :: ['piroxicam']

entities_list: @entity4832 :: ('MESH:D011142', 'Chemical') :: ['poly(vinyl alcohol)']

entities_list: @entity4653 :: ('MESH:D004401', 'Disease') :: ['SEM', 'scanning electron microscopy']

answer: @entity5230 :: (MESH:D010894,Chemical) :: ['piroxicam']


abstract: Rectal prolapse associated with traumatic @entity1241 is a rare clinical combination. This study was designed to assess Delorme's operation with sphincteroplasty as a surgical management of this combination in terms of recurrence and improvement of @entity1241 . In this prospective study, we enrolled @entity1 suffering from short, full-thickness rectal prolapse associated with traumatic @entity1241 who had been admitted to Alexandria Main University Hospital during the period of May 2010-January 2013. Preoperative data including cause of @entity130 , duration of symptoms, results of anal manometry, and degree of @entity1241 using Wexner score were collected from all @entity1 . Delorme's procedure with overlap sphincteroplasty was done in all @entity1 . Recurrence of prolapse and improvement of @entity1241 were assessed after 1, 3, 6 and 12 months. The study included 13 @entity1 aged (32  8.7) years, 9 females and 4 males. Cause of sphincteric injury included previous anal surgery in 7 @entity1 and normal labor in 6 @entity1 . Duration between sphincteric injury and operation was (8.08  2.47) months. Preoperative Wexner's mean score was 16.07  3.4. Early postoperative complications included @entity2737 (69.2%), minor wound dehiscence (61.5%), and @entity86 (7.6%). Recurrence was detected in 1 @entity1 at 6 month follow-up. Wexner's score showed significant improvement for all @entity1 after 6 months (4.00  2.04). In conclusion, combination of Delorme's procedure and sphincteroplasty for treatment of @entity1 with short complete rectal prolapse associated with traumatic @entity1241 is a safe, effective surgical management with satisfactory results regarding anatomical and functional outcomes.

title: Delorme's operation plus sphincteroplasty for complete rectal prolapse associated with traumatic XXXX .

entities_list: @entity2737 :: ('MESH:D014946', 'Disease') :: ['superficial wound infection']

entities_list: @entity86 :: ('MESH:D019106', 'Disease') :: ['postoperative bleeding']

entities_list: @entity1241 :: ('MESH:D005242', 'Disease') :: ['fecal incontinence']

answer: @entity1241 :: (MESH:D005242,Disease) :: ['fecal incontinence']


abstract: BACKGROUND: The advent of three-dimensional stereo-photogrammetry in recent years has vastly helped the craniomaxillofacial field improve in terms of preoperative and intraoperative decision making. With regard to the auricle though, there is paucity of research as to the application of this promising technology. METHODS: A total of 20 normal adult ears were included in this study. Thirteen anthropometric measurements were taken, twice by two plastic surgeons using @entity4629 ( @entity4629 ) and through images captured via 3dMD   . The purpose was to compare the reliability of measurements involving the two instruments. RESULTS: The overall mean absolute differences (MADs) of all ear anthropometries of @entity4629 and 3dMD    were 0.52  mm (range: 0.28-0.72  mm) and 0.27  mm (range: 0.15-0.53  mm), respectively, and the grand mean relative error magnitudes (REMs) were 2.85% (range: 1.01-5.99%) and 1.57% (range: 0.48-3.62%), respectively, across observers. Thus, the precision of all ear anthropometries across observers was high in both methods, but the precision of 3dMD was better than @entity4629 irrespective of observers. In addition, the MADs were less than a millimeter across all measurements. CONCLUSION: The application of three-dimensional technology in @entity9407 surgery for both template production and soft tissue analysis leads to improved planning and satisfactory results with fewer complications. We believe that with further refinement and enhancement, the use of this innovation will pave the way for prefabricated, individualized autologous or biocompatible alloplastic implantable frameworks based on an accurate mirror image of each @entity1 's normal ear in unilateral cases and in bilateral cases, appropriately sized.

title: Precision of three-dimensional stereo-photogrammetry (3dMD   ) in anthropometry of the auricle and its application in XXXX reconstruction.

entities_list: @entity4629 :: ('MESH:D051556', 'Disease') :: ['DM', 'direct measurement']

answer: @entity9407 :: (MESH:D065817,Disease) :: ['microtia']


abstract: The dim light @entity2493 onset (DLMO) is the most reliable measure of central circadian timing in @entity1 . However, it is not always possible to measure the DLMO because sample collection has to occur in the hours before usual sleep onset, it requires staff support and considerable @entity1 effort, and it is relatively expensive. Questionnaires that ask @entity1 about the timing of their behavior, such as their sleep, may provide an easier and less expensive estimate of circadian timing. The objective of this analysis was to compare the MEQ score derived from the Morningness-Eveningness Questionnaire (MEQ) and the MSFsc derived from the Munich ChronoType Questionnaire (MCTQ) to the DLMO in the largest sample to date (N = 60). Our hypothesis was that MSFsc would correlate more highly with the DLMO than MEQ score. Our sample of 36 healthy controls and 24 @entity1 with delayed @entity25 ranged in age from 18 to 62 years. All @entity1 slept at times of their own choosing for a week before the assessment of their DLMO. The DLMO correlated significantly with both the MEQ score (r = -0.70, p < 0.001) and MSFsc (r = 0.68, p < 0.001). A linear regression using MEQ, MSFsc, and age to predict the DLMO explained 60% of the DLMO variance. The strongest predictor of the DLMO was MSFsc (beta = 0.51, p = 0.001), followed by MEQ (beta = -0.41, p = 0.004), and age (beta = 0.26, p = 0.013). The beta values for MSFsc and MEQ score were not statistically different from each other. Nonetheless, around a 4-h range in the DLMO was observed at a given MEQ score and a given MSFsc, indicating that neither questionnaire should be exclusively used to time light or exogenous @entity2493 treatment, as this could result in the mistiming of these treatments relative to the DLMO, thereby potentially worsening circadian misalignment.

title: Comparing the Morningness-Eveningness Questionnaire and Munich ChronoType Questionnaire to the Dim Light XXXX Onset.

entities_list: @entity2493 :: ('MESH:D008550', 'Chemical') :: ['melatonin']

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'humans', 'patients', 'participant', 'people']

entities_list: @entity25 :: ('MESH:D012893', 'Disease') :: ['sleep phase disorder']

answer: @entity2493 :: (MESH:D008550,Chemical) :: ['Melatonin']


abstract: PURPOSE: Multiplex genomic tests are enabling oncologists to interrogate the DNA of their @entity1 . However, few oncologists are proficient with respect to the implications of complex molecular diagnostics. We initiated a Molecular Tumor Board that focused on individual @entity1 with advanced @entity5 whose @entity5 underwent genomic profiling, and here report our experience with @entity0 . METHODS: A multidisciplinary team that included physicians, scientists, geneticists, and bioinformatics/pathway specialists attended. All molecular tests were performed in a Clinical Laboratory Improvement Amendments environment (next-generation sequencing, 182 or 236 genes). RESULTS: Forty of 43 @entity1 (93%; mean age, 59 years) had at least one theoretically actionable aberration (mean, 4.79 anomalies/ @entity1 ). Median time from ordering to report was 27 days (median of approximately 11 days for specimen acquisition and approximately 14 days for diagnostic processing). Even if we considered distinct abnormalities in a gene as the same, there were only two @entity1 with an identical molecular profile. Seventy-three genes (206 abnormalities; 119 distinct) were aberrant. Seventeen of the 43 @entity1 (40%; median, seven previous therapies in the metastatic setting) were treated in a manner consistent with Molecular Tumor Board discussions; seven (16% of 43, or 41% of 17) achieved stable disease for 6 or more months (n = 2) or partial remission (n = 5). Lack of access to targeted medication was the most common reason that @entity1 could not be treated. CONCLUSION: @entity4310 boards may help to optimize the management of @entity1 with advanced, heavily pretreated @entity0 who have undergone genomic testing. Facilitating availability of appropriately targeted drugs and clinical trials is needed.

title: XXXX Experience of the Molecular Tumor Board at the University of California, San Diego Moores Cancer Center.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer', 'tumors']

entities_list: @entity4310 :: ('MESH:D009386', 'Disease') :: ['Multidisciplinary molecular tumor']

answer: @entity0 :: (MESH:D001943,Disease) :: ['Breast Cancer']


abstract: AIMS: We examined prescription patterns in maintenance treatment for recovered @entity162 @entity1 and compared these with acute treatments. METHODS: Using retrospective methods, the @entity162 @entity1 in clinical recovery (Clinical Global Impression Bipolar Version score    <=   2 for 6 months) after acute episode were selected. We reviewed differences between prescription patterns at remission and after a maintenance period of at least 6 months. RESULTS: A total of 340 @entity162 @entity1 were selected. During the maintenance period, more than half of the @entity1 (192, 56.5%) took a @entity1316 ( @entity1316 )   +   antipsychotic (AP) combination. Among the @entity1316 , @entity1092 (149, 43.8%) was most prescribed, and @entity1091 (98, 28.8%) was second, but as @entity1 moved into maintenance treatment, @entity1091 use decreased, and the use of @entity2812 (86, 25.3%) increased. Preferred AP were @entity1089 (125, 36.8%), @entity1770 (67, 19.7%), @entity1090 (48, 14.1%), and @entity1037 (39, 11.5%). The use of @entity1037 in maintenance was greatly decreased compared with that during acute treatment (67, 19.7%). Most @entity1 did not take an antidepressant (AD), but the proportion using one or more AD was increased during maintenance (17.9% to 30.3%), and @entity752 (28, 8.2%) was the preferred AD. Doses were decreased in all drugs, but @entity2812 was maintained at a dose of 133.2        68.5   mg/day. CONCLUSIONS: The most common prescription combination for @entity162 maintenance treatment was @entity1316   +   AP. The use of AP was decreased, whereas the use of AD in combination with @entity1316 and/or AP was increased. The doses of @entity1316 and AP were generally decreased during the maintenance periods, with the exception of @entity2812 .

title: Current prescription pattern of maintenance treatments for XXXX @entity1 in Korea: A focus on the transition from acute treatments.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity162 :: ('MESH:D001714', 'Disease') :: ['bipolar disorder', 'bipolar']

entities_list: @entity1092 :: ('MESH:D014635', 'Chemical') :: ['valproate']

entities_list: @entity1770 :: ('MESH:C094645', 'Chemical') :: ['aripiprazole']

entities_list: @entity1316 :: ('MESH:D019964', 'Disease') :: ['MS', 'mood stabilizer']

entities_list: @entity752 :: ('MESH:D016642', 'Chemical') :: ['bupropion']

entities_list: @entity1037 :: ('MESH:C076029', 'Chemical') :: ['olanzapine']

entities_list: @entity2812 :: ('MESH:C047781', 'Chemical') :: ['lamotrigine']

entities_list: @entity1089 :: ('MESH:C069541', 'Chemical') :: ['quetiapine']

entities_list: @entity1090 :: ('MESH:D018967', 'Chemical') :: ['risperidone']

answer: @entity162 :: (MESH:D001714,Disease) :: ['bipolar']


abstract: AIMS: We examined prescription patterns in maintenance treatment for recovered @entity162 @entity1 and compared these with acute treatments. METHODS: Using retrospective methods, the @entity162 @entity1 in clinical recovery (Clinical Global Impression Bipolar Version score    <=   2 for 6 months) after acute episode were selected. We reviewed differences between prescription patterns at remission and after a maintenance period of at least 6 months. RESULTS: A total of 340 @entity162 @entity1 were selected. During the maintenance period, more than half of the @entity1 (192, 56.5%) took a @entity1316 ( @entity1316 )   +   antipsychotic (AP) combination. Among the @entity1316 , @entity1092 (149, 43.8%) was most prescribed, and @entity1091 (98, 28.8%) was second, but as @entity1 moved into maintenance treatment, @entity1091 use decreased, and the use of @entity2812 (86, 25.3%) increased. Preferred AP were @entity1089 (125, 36.8%), @entity1770 (67, 19.7%), @entity1090 (48, 14.1%), and @entity1037 (39, 11.5%). The use of @entity1037 in maintenance was greatly decreased compared with that during acute treatment (67, 19.7%). Most @entity1 did not take an antidepressant (AD), but the proportion using one or more AD was increased during maintenance (17.9% to 30.3%), and @entity752 (28, 8.2%) was the preferred AD. Doses were decreased in all drugs, but @entity2812 was maintained at a dose of 133.2        68.5   mg/day. CONCLUSIONS: The most common prescription combination for @entity162 maintenance treatment was @entity1316   +   AP. The use of AP was decreased, whereas the use of AD in combination with @entity1316 and/or AP was increased. The doses of @entity1316 and AP were generally decreased during the maintenance periods, with the exception of @entity2812 .

title: Current prescription pattern of maintenance treatments for @entity162 XXXX in Korea: A focus on the transition from acute treatments.

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: BACKGROUND: Many factors are associated with @entity11598 ( @entity11598 ) phenomenon in @entity583 ( @entity583 ), including plasma @entity413 , age, and pre-percutaneous coronary intervention (PCI) @entity715 score. Initial clinical assessment would benefit from accurate @entity11598 prediction. This study aimed to develop a simple scoring system to predict the risk of @entity11598 in @entity1 undergoing primary PCI with @entity583 . METHODS: Baseline clinical and procedural variables were used for risk score development (the training dataset, n   =   912) and validation (the test dataset, n   =   864). Independent predictors of @entity11598 from the multivariable model were assigned integer weights based on their coefficients and incorporated into a risk score. The discriminant ability of the score was tested by receiver operating characteristic analysis using the test dataset. RESULTS: The final model included 7 significant variables, which were age, pain-to-PCI time, neutrophil count, admission plasma @entity413 level, pre-PCI @entity715 score, collateral circulation, and Killip class. All these variables were then used to build a risk score in terms of the prediction of @entity11598 . Receiver operating characteristic analysis demonstrated good risk prediction with a c statistic of 0.800 (95% confidence interval: 0.772-0.826) in the test dataset. CONCLUSIONS: In @entity1 with @entity583 treated by primary PCI, incidence of @entity11598 phenomenon may be predicted with an acceptable accuracy based on a 7-item simplified risk score.

title: A Risk Score for No Reflow in @entity1 With ST-Segment Elevation XXXX After Primary Percutaneous Coronary Intervention.

entities_list: @entity583 :: ('MESH:D009203', 'Disease') :: ['STEMI', 'ST-segment elevation myocardial infarction']

entities_list: @entity715 :: ('MESH:D013927', 'Disease') :: ['thrombus']

entities_list: @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose']

answer: @entity583 :: (MESH:D009203,Disease) :: ['Myocardial Infarction']


abstract: BACKGROUND: Many factors are associated with @entity11598 ( @entity11598 ) phenomenon in @entity583 ( @entity583 ), including plasma @entity413 , age, and pre-percutaneous coronary intervention (PCI) @entity715 score. Initial clinical assessment would benefit from accurate @entity11598 prediction. This study aimed to develop a simple scoring system to predict the risk of @entity11598 in @entity1 undergoing primary PCI with @entity583 . METHODS: Baseline clinical and procedural variables were used for risk score development (the training dataset, n   =   912) and validation (the test dataset, n   =   864). Independent predictors of @entity11598 from the multivariable model were assigned integer weights based on their coefficients and incorporated into a risk score. The discriminant ability of the score was tested by receiver operating characteristic analysis using the test dataset. RESULTS: The final model included 7 significant variables, which were age, pain-to-PCI time, neutrophil count, admission plasma @entity413 level, pre-PCI @entity715 score, collateral circulation, and Killip class. All these variables were then used to build a risk score in terms of the prediction of @entity11598 . Receiver operating characteristic analysis demonstrated good risk prediction with a c statistic of 0.800 (95% confidence interval: 0.772-0.826) in the test dataset. CONCLUSIONS: In @entity1 with @entity583 treated by primary PCI, incidence of @entity11598 phenomenon may be predicted with an acceptable accuracy based on a 7-item simplified risk score.

title: A Risk Score for No Reflow in XXXX With ST-Segment Elevation @entity583 After Primary Percutaneous Coronary Intervention.

answer: @entity1 :: (9606,Species) :: ['Patients']


abstract: BACKGROUND: The Walgreens Connected Care @entity15 (CCMS) treatment management program provides enhanced levels of monitoring, oversight, and care for @entity1 taking MS disease-modifying agents. This study compared rates of adherence to MS medications for @entity1 participating in the CCMS program for at least 6 months with those for @entity1 participating for less than 6 months. For a subsample of @entity1 , we also examined the relationship between adherence and the presence of @entity1295 or @entity308 . METHODS: This was a retrospective study of @entity1 new to the CCMS program and followed up for 1 year of participation. Adherence to MS medications was measured as the proportion of days covered, with propensity scores used to match the CCMS intervention group to the less-managed comparison group. The impact of program participation on the relationship between @entity308 or @entity1295 and adherence over time was a separate analysis. RESULTS: Mean proportion of days covered rates improved significantly in the group managed for at least 6 months compared with those who were less managed. Positive screenings for @entity1295 and @entity308 reduced adherence in the less-managed group but not in @entity1 with longer participation in the program. CONCLUSIONS: Overall, the CCMS program significantly increased adherence to MS medications. This improved adherence was not negatively impacted by positive screenings for @entity1295 and @entity308 .

title: Walgreens connected care: impact of managed therapy on adherence to medications used to treat XXXX and related comorbid conditions.

entities_list: @entity308 :: ('MESH:D003866', 'Disease') :: ['depression']

entities_list: @entity15 :: ('MESH:D009103', 'Disease') :: ['Multiple Sclerosis']

answer: @entity15 :: (MESH:D009103,Disease) :: ['multiple sclerosis']